Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $651,780.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kymera Therapeutics Trading Down 2.4 %

Shares of Kymera Therapeutics stock traded down $1.18 on Tuesday, reaching $47.30. 327,736 shares of the stock were exchanged, compared to its average volume of 627,109. Kymera Therapeutics, Inc. has a 1-year low of $9.60 and a 1-year high of $50.19. The firm has a market capitalization of $2.90 billion, a PE ratio of -19.31 and a beta of 2.22. The business has a fifty day moving average price of $44.57 and a two-hundred day moving average price of $38.89.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The company had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. During the same period in the previous year, the firm posted ($0.67) EPS. Kymera Therapeutics’s revenue was up 55.2% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KYMR. Price T Rowe Associates Inc. MD boosted its stake in Kymera Therapeutics by 18.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares during the last quarter. Norges Bank acquired a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $12,834,000. Artal Group S.A. lifted its holdings in shares of Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Kymera Therapeutics by 229.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock worth $17,177,000 after acquiring an additional 469,947 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on KYMR shares. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. B. Riley lifted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Oppenheimer restated an “outperform” rating and set a $52.00 target price on shares of Kymera Therapeutics in a report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Finally, Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $48.67.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.